
  
    
      
        DESCRIPTION_NNP of_IN CASE_NN
        An_DT 18_CD -_: year-old_JJ Caucasian_NNP male_JJ with_IN type_NN 1_CD diabetes_NN presented_VBN to_TO the_DT emergency_NN department_NN
        complaining_VBG of_IN severe_JJ left_JJ knee_NN pain_NN and_CC swelling_VBG after_IN sustaining_VBG a_DT knee_NN injury_NN that_WDT
        occurred_VBD during_IN a_DT high_JJ school_NN football_NN match_NN ._. Joint_NNP effusions_NNS were_VBD visible_JJ and_CC palpable_JJ
        above_IN the_DT left_NN knee_NN ,_, and_CC there_EX was_VBD significant_JJ loss_NN of_IN smooth_JJ motion_NN of_IN the_DT knee_NN ,_, passively_RB
        performed_VBN ._. Plain_NNP X_NNP rays_NNS showed_VBD no_DT signs_NNS of_IN fractures_NNS ._. The_DT patient_NN had_VBD had_VBN type_NN 1_CD diabetes_NN
        for_IN six_CD years_NNS ,_, and_CC his_PRP$ insulin_NN regimen_NN consisted_VBD of_IN insulin_NN glargine_NN ,_, 35_CD units_NNS at_IN 8_CD :_: 00_CD
        p_NN ._. m_NN ._. ,_, and_CC insulin_NN lispro_NN ,_, 23_CD units_NNS at_IN 8_CD :_: 00_CD a_DT ._. m_NN ._. and_CC 16_CD units_NNS at_IN 8_CD :_: 00_CD p_NN ._. m_NN ._. The_DT patient_NN had_VBD
        no_DT apparent_JJ complications_NNS related_VBN to_TO type_NN 1_CD diabetes_NN ._.
        On_IN examination_NN he_PRP was_VBD alert_VB ,_, his_PRP$ pulse_NN was_VBD 76_CD bpm_NN regular_JJ ,_, and_CC his_PRP$ blood_NN pressure_NN was_VBD
        118_CD /_NN 66_CD mm_NN Hg_NNP ._. Recently_RB ,_, the_DT patient_NN had_VBD had_VBN frequent_JJ episodes_NNS of_IN both_DT hyperglycemia_NN and_CC
        hypoglycemia_NN ._. However_RB ,_, he_PRP had_VBD never_RB developed_VBN diabetic_JJ ketoacidosis_NNS (_( DKA_NNP )_) ._. His_PRP$ recent_JJ HbA_NNP 1_CD c_SYM
        was_VBD 9_CD ._. 5_CD %_NN ,_, demonstrating_VBG inadequate_JJ glycemic_JJ control_NN ._.
        The_DT patient_NN was_VBD referred_VBN to_TO an_DT orthopedic_JJ surgeon_NN ,_, and_CC arthroscopy_NN was_VBD scheduled_VBN a_DT few_JJ
        days_NNS later_RB ._. A_DT complex_JJ tear_VB of_IN the_DT medial_NN meniscus_JJ extending_VBG to_TO the_DT articular_NN surfaces_VBZ was_VBD
        diagnosed_VBN ._. Partial_NNP meniscectomy_NN was_VBD recommended_VBN ._. (_( This_DT procedure_NN usually_RB takes_VBZ about_IN one_CD
        hour—nonetheless_JJ ,_, the_DT preoperative_JJ preparation_NN for_IN general_JJ anesthesia_NN and_CC the_DT postoperative_JJ
        recovery_NN may_MD add_VB several_JJ hours_NNS to_TO this_DT time_NN ._. )_)
        
          When_WRB Would_MD You_PRP Have_VB This_DT Patient_NNP Report_NNP to_TO the_DT Hospital_NNP ?_. The_DT Day_NNP before_IN Surgery_NNP or_CC
          the_DT Morning_NNP of_IN Surgery_NNP ?_.
          This_DT patient_NN should_MD be_VB hospitalized_VBN no_RB later_RBR than_IN the_DT evening_NN before_IN surgery_NN ,_, given_VBN
          his_PRP$ history_NN of_IN frequent_JJ episodes_NNS of_IN hypo-_NN and_CC hyperglycemia_NN and_CC his_PRP$ poor_JJ glycemic_JJ
          control_NN ._. This_DT should_MD allow_VB for_IN final_JJ optimization_NN of_IN glucose_NN control_NN before_IN surgery_NN ._.
          Ideally_RB ,_, frequent_JJ contact_NN with_IN the_DT patient_NN and_CC adjustment_NN of_IN the_DT insulin_NN regimen_NN prior_RB to_TO
          surgery_NN should_MD lead_VB to_TO an_DT excellent_JJ glycemic_JJ control_NN ._. This_DT 18_CD -_: year-old_JJ patient_NN on_IN
          glargine_NN might_MD benefit_VB from_IN additional_JJ doses_NNS of_IN lispro_NN given_VBN before_IN lunch_NN and_CC dinner_NN
          (_( rather_RB than_IN at_IN 8_CD p_NN ._. m_NN ._. ,_, unless_IN this_DT is_VBZ before_IN dinner_NN )_) ._.
          A_DT patient_NN with_IN poorly_RB controlled_VBN diabetes_NN should_MD not_RB undergo_VB elective_JJ surgery_NN until_IN
          glycemic_JJ levels_NNS are_VBP reasonably_RB controlled_VBN ._. For_IN example_NN ,_, bringing_VBG the_DT patient_NN into_IN the_DT
          hospital_NN with_IN blood_NN glucose_NN levels_NNS of_IN 450_CD mg_NN /_NN dl_NN will_MD likely_JJ result_VB in_IN a_DT canceled_VBN surgery_NN ._.
          If_IN a_DT patient_NN is_VBZ scheduled_VBN for_IN day_NN of_IN admission_NN surgery_NN ,_, one_CD way_NN to_TO avoid_VB having_VBG to_TO send_VB
          the_DT patient_NN out_IN without_IN being_VBG able_JJ to_TO do_VB the_DT procedure_NN is_VBZ to_TO perform_VB a_DT finger_NN stick_NN blood_NN
          sugar_NN on_IN arrival_NN so_IN one_PRP can_MD cancel_VB before_IN admission_NN ._.
          Patients_NNS undergoing_VBG minor_JJ surgical_JJ procedures_NNS (_( e_SYM ._. g_SYM ._. ,_, arthroscopy_NN )_) may_MD be_VB brought_VBN to_TO
          the_DT hospital_NN on_IN the_DT morning_NN of_IN surgery_NN ._. As_IN the_DT patient_NN is_VBZ usually_RB NPO_NNP (_( i_NNP ._. e_SYM ._. ,_, has_VBZ been_VBN
          given_VBN orders_NNS to_TO fast_RB before_IN the_DT surgery_NN )_) ,_, a_DT lower_JJR dose_NN of_IN the_DT intermediate-_NN or_CC
          long-acting_JJ insulin_NN is_VBZ administered_VBN ,_, and_CC the_DT regular_JJ insulin_NN is_VBZ withheld_VBN (_( Box_NNP 1_LS )_) ._. Insulin_NNP
          therapy_NN should_MD never_RB be_VB withheld_VBN in_IN a_DT patient_NN with_IN type_NN 1_CD diabetes_NN as_IN this_DT can_MD result_VB in_IN
          DKA_NNP ._.
        
        
          How_WRB Should_MD His_PRP$ Insulin_NNP Be_VB Managed_VBN before_IN Surgery_NNP ?_.
          The_DT degree_NN of_IN metabolic_JJ control_NN should_MD be_VB carefully_RB evaluated_VBN before_IN surgery_NN ;_: the_DT goal_NN
          is_VBZ to_TO improve_VB the_DT patient_NN 's_POS blood_NN glucose_NN readings_NNS on_IN an_DT outpatient_NN basis_NN before_IN
          undergoing_VBG surgery_NN ._. If_IN hyperglycemia_NN has_VBZ been_VBN present_JJ for_IN a_DT prolonged_JJ period_NN of_IN time_NN
          before_IN surgery_NN ,_, this_DT could_MD result_VB in_IN dehydration_NN ,_, which_WDT is_VBZ commonly_RB associated_VBN with_IN
          electrolytic_JJ abnormalities_NNS such_JJ as_IN sodium_NN and_CC potassium_NN loss_NN and_CC possibly_RB intravascular_NN
          volume_NN depletion_NN ._. Prolonged_NNP hyperglycemia_NN will_MD delay_VB healing_VBG and_CC increase_VB the_DT risk_NN of_IN
          ischemia_NN ._. A_DT number_NN of_IN observations_NNS have_VBP indicated_VBN that_IN hyperglycemia_NN impairs_NNS collagen_NN
          formation_NN and_CC causes_VBZ a_DT decrease_NN in_IN the_DT tensile_NN strength_NN of_IN surgical_JJ wounds_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. Simply_RB
          avoiding_VBG hyperglycemia_NN can_MD prevent_VB these_DT consequences_NNS ._. The_DT reduction_NN of_IN glucose_NN levels_NNS to_TO
          below_IN 200_CD mg_NN /_NN dl_NN has_VBZ been_VBN shown_VBN to_TO improve_VB granulocyte_NN adherence_NN and_CC granulocytosis_NNS ,_, both_DT
          key_JJ components_NNS of_IN the_DT innate_JJ immunity_NN and_CC the_DT defense_NN against_IN bacterial_JJ infections_NNS ._.
          Studies_NNS in_IN both_DT humans_NNS and_CC animals_NNS suggest_VBP that_IN high_JJ glucose_NN levels_NNS might_MD exacerbate_VB
          ischemic_JJ brain_NN damage_NN [_NN 3_CD ]_NN ._.
          Admission_NNP to_TO the_DT hospital_NN is_VBZ recommended_VBN for_IN all_DT patients_NNS with_IN type_NN 1_CD diabetes_NN ,_, and_CC a_DT
          stabilization_NN period_NN of_IN 12_CD –_NN 16_CD hours_NNS is_VBZ also_RB recommended_VBN for_IN urgent_JJ procedures_NNS if_IN severe_JJ
          hyperglycemia_NN is_VBZ present_JJ [_NN 4_CD ,_, 5_CD ]_NN ._. However_RB ,_, the_DT widespread_JJ use_NN of_IN home_NN blood_NN glucose_NN
          monitoring_VBG makes_VBZ the_DT improvement_NN of_IN glycemic_JJ control_NN possible_JJ prior_RB to_TO admission_NN ._.
          Traditionally_RB ,_, long-acting_JJ (_( e_SYM ._. g_SYM ._. ultralente_NN )_) insulin_NN is_VBZ discontinued_VBN 2_CD –_NN 3_CD days_NNS before_IN
          surgery_NN ,_, and_CC the_DT patient_NN is_VBZ stabilized_VBN on_IN a_DT regimen_NN of_IN intermediate-acting_JJ (_( neutral_JJ
          protamine_NN hagedorn_NN [_NN NPH_NNP ]_NN or_CC lente_NN )_) and_CC short-acting_JJ (_( regular_JJ or_CC humalog_NN )_) insulin_NN twice_RB a_DT
          day_NN ,_, or_CC regular_JJ insulin_NN before_IN meals_NNS and_CC intermediate-acting_JJ insulin_NN at_IN bedtime_NN ._. However_RB ,_,
          if_IN the_DT glycemic_JJ control_NN is_VBZ good_JJ and_CC the_DT patient_NN is_VBZ being_VBG treated_VBN with_IN glargine_NN ,_, it_PRP is_VBZ
          acceptable_JJ to_TO continue_VB the_DT regimen_NN until_IN the_DT day_NN of_IN surgery_NN [_NN 3_CD ]_NN ._. Alternatively_RB ,_, 1_CD /_NN 2_CD –_NN 2_CD /_NN 3_CD
          of_IN the_DT usual_JJ insulin_NN regimen_NN is_VBZ given_VBN on_IN the_DT day_NN of_IN the_DT procedure_NN [_NN 3_CD ]_NN ._. On_IN the_DT morning_NN of_IN
          surgery_NN patients_NNS with_IN type_NN 1_CD diabetes_NN should_MD receive_VB the_DT insulin_NN regimen_NN that_WDT is_VBZ used_VBN
          intraoperatively_RB (_( Box_NNP 2_LS )_) [_NN 6_CD ]_NN ._.
          Evaluation_NNP of_IN metabolic_JJ homeostasis_NNS ,_, lipid_NN profile_NN ,_, and_CC kidney_NN and_CC myocardial_NN function_NN
          must_MD be_VB completed_VBN before_IN surgery_NN ._. The_DT presence_NN of_IN diabetic_JJ autonomic_JJ neuropathy_NN should_MD
          also_RB be_VB assessed_VBN prior_RB to_TO surgery_NN because_IN this_DT condition_NN predisposes_NNS to_TO perioperative_JJ
          hypotension_NN ._. In_IN such_JJ patients_NNS meticulous_JJ monitoring_NN of_IN blood_NN pressure_NN and_CC volume_NN status_NN
          is_VBZ essential_JJ during_IN the_DT perioperative_JJ period_NN [_NN 7_CD ]_NN ._.
          The_DT common_JJ agreement_NN is_VBZ that_IN 4_CD –_NN 8_CD hours_NNS before_IN surgery_NN ,_, the_DT patient_NN should_MD be_VB kept_VBN NPO_NNP ,_,
          subcutaneous_JJ (_( SC_NNP )_) insulin_NN should_MD be_VB discontinued_VBN ,_, and_CC an_DT intravenous_JJ (_( IV_NNP )_) infusion_NN line_NN
          should_MD be_VB inserted_VBN ._. It_PRP should_MD be_VB emphasized_VBN that_IN if_IN the_DT elective_JJ surgical_JJ procedure_NN can_MD
          be_VB scheduled_VBN for_IN early_JJ morning_NN hours_NNS and_CC the_DT procedure_NN lasts_VBZ at_IN least_JJS four_CD hours_NNS ,_, this_DT
          limits_VBZ the_DT NPO_NNP to_TO about_IN 4_CD –_NN 6_CD hours_NNS and_CC allows_VBZ administration_NN of_IN usual_JJ or_CC 1_CD /_NN 2_CD –_NN 2_CD /_NN 3_CD usual_JJ
          insulin_NN and_CC use_NN of_IN a_DT glucose_NN infusion_NN to_TO replace_VB breakfast_NN and_CC supplemental_JJ insulin_NN
          either_CC subcutaneously_RB or_CC intravenously_RB ._. If_IN both_DT glucose_NN and_CC insulin_NN are_VBP infused_VBN ,_, it_PRP
          should_MD be_VB pointed_VBN out_RP that_IN these_DT must_MD be_VB two_CD separately_RB controlled_VBN infusions_NNS ,_, so_RB glucose_NN
          and_CC insulin_NN infusion_NN can_MD be_VB varied_VBN independently_RB ._.
        
        
          How_WRB Should_MD His_PRP$ Insulin_NNP Be_VB Managed_VBN during_IN Surgery_NNP ?_.
          Major_JJ surgery_NN and_CC general_JJ anesthesia_NN can_MD cause_VB severe_JJ metabolic_JJ abnormalities_NNS in_IN
          patients_NNS with_IN type_NN 1_CD diabetes_NN ._. Given_VBN the_DT limitations_NNS of_IN SC_NNP insulin_NN therapy_NN ,_, such_JJ as_IN
          unpredictable_JJ absorption_NN and_CC variable_JJ plasma_NN insulin_NN levels_NNS ,_, constant_JJ infusion_NN of_IN insulin_NN
          is_VBZ recommended_VBN [_NN 3_CD ]_NN ._. Anesthesia_NNP induces_VBZ complex_JJ neuroendocrine_NN stress_NN responses_NNS and_CC
          activates_NNS the_DT sympathetic_JJ nervous_JJ system_NN ._. The_DT abnormal_JJ release_NN of_IN growth_NN hormone_NN ,_,
          cortisol_NN ,_, and_CC epinephrine_NN leads_VBZ to_TO impaired_VBN insulin_NN secretion_NN ,_, and_CC causes_NNS insulin_NN
          resistance_NN and_CC hyperglycemia_NN due_JJ to_TO increased_VB glycogenolysis_NNS ,_, gluconeogenesis_NNS ,_, and_CC
          decreased_VBD glucose_NN disposal_NN ._. Many_JJ other_JJ conditions_NNS may_MD cause_VB severe_JJ insulin_NN resistance_NN in_IN
          a_DT patient_NN with_IN diabetes_NN (_( Box_NNP 3_LS )_) ._.
          For_IN patients_NNS scheduled_VBN for_IN elective_JJ surgery_NN ,_, IV_NNP insulin_NN and_CC glucose_NN infusion_NN are_VBP
          usually_RB started_VBN several_JJ hours_NNS preoperatively_RB ,_, and_CC glucose_NN levels_NNS should_MD be_VB maintained_VBN
          between_IN 100_CD and_CC 125_CD mg_NN /_NN dl_NN ._. Slightly_RB higher_JJR targets_NNS (_( 100_CD –_NN 150_CD mg_NN /_NN dl_NN )_) have_VBP been_VBN recommended_VBN
          by_IN some_DT diabetologists_NNS to_TO minimize_VB the_DT risk_NN of_IN hypoglycemia_NN ._. The_DT maintenance_NN of_IN glucose_NN
          levels_NNS below_IN 200_CD mg_NN /_NN dl_NN has_VBZ been_VBN shown_VBN to_TO prevent_VB bacterial_JJ infections_NNS and_CC ischemic_JJ brain_NN
          damage_NN [_NN 3_CD ,_, 8_CD ]_NN ._. Suggested_NNP guidelines_NNS for_IN management_NN of_IN patients_NNS with_IN type_NN 1_CD diabetes_NN by_IN use_NN
          of_IN insulin_NN are_VBP outlined_VBN in_IN Box_NNP 2_CD ._. Since_IN IV_NNP regular_JJ insulin_NN has_VBZ a_DT short_JJ half-life_NN (_( ten_CD
          minutes_NNS )_) ,_, hypoglycemia_NN is_VBZ of_IN little_JJ concern_NN ,_, as_IN the_DT infusion_NN can_MD be_VB decreased_VBN and_CC the_DT IV_NNP
          glucose_NN rate_NN increased_VBD ._. The_DT infusion_NN rate_NN can_MD be_VB adjusted_VBN by_IN a_DT floor_NN nurse_NN before_IN surgery_NN
          and_CC by_IN the_DT anesthesiologist_NN intraoperatively_RB ._. An_DT insulin_NN infusion_NN algorithm_NN is_VBZ
          constructed_VBN to_TO allow_VB easy_JJ titration_NN of_IN the_DT insulin_NN dose_NN ,_, and_CC IV_NNP glucose_NN must_MD also_RB be_VB
          infused_VBN to_TO obtain_VB glucose_NN levels_NNS within_IN target_NN (_( Box_NNP 2_LS )_) ._. This_DT type_NN of_IN algorithm_NN is_VBZ
          effective_JJ in_IN the_DT majority_NN of_IN patients_NNS ;_: however_RB ,_, it_PRP is_VBZ based_VBN on_IN the_DT “ average_JJ” patient_NN and_CC
          might_MD require_VB individualization_NN ._. If_IN the_DT patient_NN has_VBZ a_DT coexisting_VBG condition_NN associated_VBN
          with_IN increased_VBN insulin_NN requirement_NN ,_, IV_NNP insulin_NN doses_NNS need_VBP to_TO be_VB increased_VBN ._. Glycemic_NNP
          levels_NNS must_MD be_VB monitored_VBN at_IN hourly_JJ intervals_NNS to_TO keep_VB glucose_NN levels_NNS between_IN 100_CD and_CC 125_CD
          mg_NN /_NN dl_NN ._.
          Patients_NNS with_IN type_NN 1_CD diabetes_NN who_WP are_VBP treated_VBN with_IN continuous_JJ SC_NNP insulin_NN infusion_NN by_IN
          an_DT insulin_NN pump_NN should_MD be_VB easily_RB converted_VBN to_TO IV_NNP regular_JJ insulin_NN infusion_NN just_RB before_IN
          surgery_NN ._. Continuous_NNP SC_NNP insulin_NN infusion_NN is_VBZ an_DT acceptable_JJ regimen_NN for_IN surgical_JJ procedures_NNS
          requiring_VBG local_JJ anesthesia_NN ._.
        
        
          How_WRB Should_MD Fluids_NNP and_CC Electrolytes_NNP Be_VB Managed_VBN in_IN This_DT Patient_NNP ?_.
          An_DT adult_NN without_IN diabetes_NN requires_VBZ a_DT minimum_NN of_IN 100_CD to_TO 125_CD grams_NNS (_( 400_CD to_TO 500_CD calories_NNS )_)
          of_IN glucose_NN per_IN day_NN to_TO prevent_VB protein_NN catabolism_NN and_CC the_DT development_NN of_IN ketosis_NNS ._. Hence_RB ,_,
          this_DT patient_NN with_IN types_NNS 1_CD diabetes_NN should_MD be_VB treated_VBN with_IN 5_CD –_NN 10_CD grams_NNS of_IN glucose_NN per_IN hour_NN
          (_( 1_CD ._. 2_LS to_TO 2_CD ._. 4_CD mg_NN /_NN kg_NN /_NN min_NN in_IN a_DT 70_CD -_: kilogram_NN subject_JJ )_) to_TO provide_VB sufficient_JJ basal_NN energy_NN
          requirement_NN and_CC prevent_VB hypoglycemia_NN during_IN surgery_NN ._. The_DT dextrose_NN concentration_NN of_IN the_DT IV_NNP
          solution_NN (_( Box_NNP 2_LS )_) is_VBZ adjusted_VBN based_VBN on_IN the_DT expected_VBN length_NN of_IN surgery_NN ._. Thus_RB ,_, in_IN this_DT case_NN
          5_CD %_NN of_IN dextrose_NN in_IN water_NN (_( D_NNP 5_CD W_NNP )_) can_MD be_VB administered_VBN intravenously_RB via_IN infusion_NN pump_NN ._. For_IN
          longer_JJR surgical_JJ procedures_NNS (_( intraabdominal_NN or_CC intrathoracic_JJ surgery_NN )_) ,_, 10_CD %_NN of_IN dextrose_NN
          should_MD be_VB used_VBN to_TO avoid_VB excessive_JJ fluid_JJ administration_NN ._. A_DT 20_CD %_NN or_CC 50_CD %_NN dextrose_NN solution_NN
          can_MD be_VB infused_VBN through_IN a_DT central_JJ venous_JJ catheter_NN if_IN fluid_JJ restriction_NN is_VBZ critical_JJ ._. If_IN
          additional_JJ fluids_NNS are_VBP required_VBN ,_, for_IN instance_NN ,_, to_TO replace_VB unexpected_JJ intraoperative_JJ blood_NN
          losses_NNS ,_, non-glucose-containing_JJ solutions_NNS should_MD be_VB administered_VBN ._.
          As_IN a_DT general_JJ rule_NN ,_, normal_JJ serum_NN potassium_NN levels_NNS do_VBP not_RB necessarily_RB imply_VB that_IN the_DT
          total_JJ body_NN potassium_NN content_NN is_VBZ normal_JJ ,_, as_RB only_RB 2_CD %_NN of_IN total_JJ body_NN potassium_NN stores_NNS are_VBP
          extracellular_NN [_NN 9_CD ]_NN ._. In_IN patients_NNS with_IN diabetes_NN ,_, the_DT metabolic_JJ homeostasis_NNS can_MD rapidly_RB be_VB
          altered_VBN and_CC many_JJ factors_NNS may_MD influence_VB serum_NN potassium_NN levels_NNS and_CC total_JJ body_NN potassium_NN
          stores_NNS ._. These_DT factors_NNS are_VBP (_( a_DT )_) insulin_NN ,_, which_WDT increases_VBZ potassium_NN uptake_NN by_IN cells_NNS ;_: (_( b_SYM )_)
          acidemia_NN ,_, which_WDT causes_VBZ hyperkalemia_NN as_IN a_DT result_NN of_IN the_DT exchange_NN of_IN intracellular_NN
          potassium_NN for_IN hydrogen_NN ions_NNS ;_: and_CC (_( c_SYM )_) hyperosmolarity_NN ,_, which_WDT causes_VBZ a_DT rearrangement_NN of_IN
          potassium_NN and_CC fluid_JJ from_IN intracellular_NN to_TO extracellular_NN compartments_NNS ._. In_IN patients_NNS with_IN
          diabetes_NN who_WP have_VBP normal_JJ renal_JJ function_NN and_CC normal_JJ serum_NN potassium_NN concentration_NN ,_, 10_CD to_TO
          20_CD mEq_NN of_IN potassium_NN should_MD be_VB added_VBN to_TO each_DT liter_NN of_IN dextrose-containing_JJ fluid_NN ._. A_DT higher_JJR
          dose_NN is_VBZ required_VBN in_IN patients_NNS with_IN hypokalemia_NN ._. If_IN serum_NN potassium_NN levels_NNS are_VBP greater_JJR than_IN
          5_CD ._. 5_CD mEq_NN /_NN l_NN ,_, potassium_NN therapy_NN should_MD be_VB withheld_VBN from_IN the_DT IV_NNP fluids_NNS and_CC potassium_NN serum_NN
          levels_NNS should_MD be_VB monitored_VBN closely_RB ._.
        
        
          How_WRB Would_MD the_DT Management_NNP of_IN This_DT Patient_NNP Be_VB Different_JJ for_IN Emergency_NNP Rather_RB Than_IN
          Elective_NNP Surgery_NNP ?_.
          It_PRP has_VBZ been_VBN estimated_VBN that_IN as_RB many_JJ as_IN 5_CD %_NN of_IN all_DT patients_NNS with_IN diabetes_NN require_VB surgery_NN
          at_IN some_DT point_NN during_IN their_PRP$ lives_NNS [_NN 3_CD ]_NN ._. Many_JJ of_IN these_DT patients_NNS undergo_VBP emergency_NN surgery_NN as_IN
          a_DT result_NN of_IN lower_JJR extremity_NN infections_NNS requiring_VBG incision_NN and_CC drainage_NN or_CC even_RB lower_JJR limb_NN
          amputations_NNS ._. More_JJR than_IN 50_CD %_NN of_IN lower_JJR limb_NN amputations_NNS in_IN the_DT United_NNP States_NNPS occur_VBP among_IN
          people_NNS with_IN diabetes_NN ._. The_DT majority_NN of_IN patients_NNS with_IN diabetes_NN admitted_VBN for_IN emergency_NN
          procedures_NNS have_VBP a_DT poor_JJ glyco-metabolic_JJ control_NN and_CC some_DT of_IN them_PRP may_MD have_VB coexisting_VBG DKA_NNP ._.
          The_DT first_JJ step_NN in_IN management_NN is_VBZ to_TO assess_VB glycemic_JJ ,_, electrolyte_NN ,_, acid-base_JJ ,_, and_CC volume_NN
          status_NN ._. An_DT IV_NNP saline_NN infusion_NN should_MD be_VB started_VBN while_IN waiting_VBG for_IN laboratory_NN tests_NNS to_TO
          correct_VB possible_JJ volume_NN loss_NN ._. Insulin_NNP infusion_NN should_MD be_VB started_VBN at_IN an_DT appropriate_JJ rate_NN
          (_( Box_NNP 2_LS )_) ,_, and_CC frequently_RB insulin_NN requirement_NN might_MD increase_VB during_IN emergency_NN surgery_NN ._. It_PRP
          is_VBZ crucial_JJ that_IN volume_NN losses_NNS and_CC electrolyte_NN abnormalities_NNS are_VBP corrected_VBN prior_RB to_TO
          surgery_NN ._.
          If_IN DKA_NNP is_VBZ diagnosed_VBN ,_, immediate_JJ treatment_NN is_VBZ indicated_VBN ,_, and_CC ,_, if_IN possible_JJ ,_, surgery_NN
          should_MD be_VB delayed_VBN until_IN the_DT glyco-metabolic_JJ control_NN is_VBZ corrected_VBN and_CC stabilized_VBN ._. If_IN
          emergency_NN surgery_NN procedures_NNS cannot_NN be_VB delayed_VBN ,_, DKA_NNP can_MD be_VB treated_VBN concurrently_RB with_IN
          surgery_NN ._.
        
        
          How_WRB Should_MD the_DT Postoperative_NNP Glyco-_NNP Metabolic_NNP Management_NNP Be_VB Handled_NNP in_IN This_DT
          Patient_NNP ?_.
          Both_DT IV_NNP insulin_NN and_CC glucose_NN (_( D_NNP 5_CD W_NNP ,_, 0_CD ._. 45_CD %_NN normal_JJ saline_NN )_) infusion_NN should_MD be_VB continued_VBN
          until_IN the_DT glycol-metabolic_JJ control_NN is_VBZ stable_JJ and_CC until_IN 1_CD –_NN 2_CD hours_NNS after_IN the_DT patient_NN is_VBZ
          able_JJ to_TO resume_VB oral_JJ feeding_NN without_IN difficulty_NN ._. If_IN postoperative_JJ nausea_NN and_CC vomiting_NN are_VBP
          present_JJ ,_, IV_NNP insulin_NN and_CC glucose_NN infusion_NN should_MD not_RB be_VB discontinued_VBN ._. Furthermore_RB ,_, in_IN
          patients_NNS with_IN type_NN 1_CD diabetes_NN ketonuria_NN could_MD be_VB an_DT early_JJ sign_NN of_IN impending_JJ DKA_NNP ,_, which_WDT
          could_MD be_VB triggered_VBN by_IN starvation_NN ._. Capillary_NNP glucose_NN should_MD be_VB monitored_VBN every_DT 1_CD –_NN 2_CD hours_NNS
          at_IN the_DT bedside_NN ,_, and_CC the_DT variable_JJ insulin_NN and_CC glucose_NN infusion_NN should_MD be_VB adjusted_VBN to_TO
          maintain_VB blood_NN glucose_NN levels_NNS between_IN 100_CD and_CC 150_CD mg_NN /_NN dl_NN (_( Box_NNP 4_LS )_) ._. Serum_NNP electrolytes_NNS
          should_MD be_VB measured_VBN immediately_RB after_IN surgery_NN ._. Hypo-_NNP and_CC hyperkalemia_NN are_VBP fairly_RB common_JJ in_IN
          the_DT postoperative_JJ period_NN and_CC should_MD be_VB corrected_VBN without_IN delay_NN ._. The_DT presence_NN of_IN a_DT widened_VBN
          anion_NN gap_NN suggests_VBZ the_DT possibility_NN of_IN DKA_NNP or_CC lactic_JJ acidosis_NNS that_WDT might_MD be_VB caused_VBN by_IN
          systemic_JJ infections_NNS or_CC hypoperfusion_NN ._.
          If_IN the_DT patient_NN is_VBZ stable_JJ and_CC can_MD tolerate_VB oral_JJ feeding_NN ,_, the_DT regular_JJ home_NN dose_NN of_IN
          insulin_NN may_MD be_VB administered_VBN 20_CD –_NN 30_CD minutes_NNS before_IN the_DT meal_NN and_CC the_DT insulin_NN infusion_NN
          stopped_VBD 15_CD –_NN 20_CD minutes_NNS after_IN the_DT meal_NN ._. Of_IN note_NN ,_, insulin_NN infusion_NN should_MD be_VB discontinued_VBN
          only_RB after_IN the_DT SC_NNP insulin_NN regimen_NN is_VBZ started_VBN to_TO avoid_VB any_DT gaps_NNS in_IN plasma_NN insulin_NN levels_NNS
          that_WDT may_MD lead_VB to_TO a_DT loss_NN of_IN metabolic_JJ control_NN ._.
          Resuming_NNP a_DT sliding_VBG scale_NN SC_NNP insulin_NN treatment_NN postoperatively_RB has_VBZ been_VBN advocated_VBN to_TO
          improve_VB metabolic_JJ control_NN in_IN patients_NNS with_IN type_NN 1_CD diabetes_NN ._. However_RB ,_, there_EX are_VBP several_JJ
          drawbacks_NNS with_IN this_DT approach_NN ._. First_LS of_IN all_DT ,_, this_DT approach_NN is_VBZ based_VBN on_IN a_DT retrospective_NN
          treatment_NN for_IN hyperglycemia_NN ,_, which_WDT reflects_VBZ the_DT degree_NN of_IN insulin_NN sensitivity_NN and_CC glucose_NN
          disposal_NN rate_NN in_IN the_DT preoperative_JJ period_NN ._. The_DT use_NN of_IN a_DT SC_NNP insulin_NN treatment_NN
          postoperatively_RB tends_VBZ to_TO create_VB fluctuations_NNS in_IN blood_NN glucose_NN levels_NNS that_WDT could_MD be_VB
          difficult_JJ to_TO control_VB ._. Moreover_RB ,_, there_EX is_VBZ a_DT risk_NN of_IN exposing_VBG the_DT patient_NN to_TO the_DT risk_NN of_IN
          hypoglycemia_NN if_IN excessive_JJ doses_NNS of_IN insulin_NN are_VBP administered_VBN ._. More_RBR importantly_RB ,_, the_DT use_NN of_IN
          a_DT sliding_VBG scale_NN treatment_NN might_MD predispose_VB to_TO DKA_NNP in_IN insulin-deficient_JJ patients_NNS before_IN
          the_DT development_NN of_IN hyperglycemic_JJ levels_NNS ._.
        
        
          What_WP Are_VBP the_DT General_NNP Principles_NNPS for_IN Surgery_NNP in_IN a_DT Patient_NNP with_IN Type_NNP 2_CD
          Diabetes_NNP ?_.
          Patients_NNS with_IN type_NN 2_CD diabetes_NN require_VB good_JJ blood_NN glucose_NN control_NN prior_RB to_TO undergoing_VBG
          surgery_NN ._. Although_IN these_DT patients_NNS seldom_RB develop_VBP DKA_NNP ,_, the_DT same_JJ adverse_JJ effects_NNS of_IN poor_JJ
          glycemic_JJ control_NN may_MD develop_VB ._. For_IN procedures_NNS that_WDT require_VBP general_JJ anesthesia_NN ,_, specific_JJ
          treatment_NN ,_, other_JJ than_IN hourly_JJ glycemic_JJ monitoring_NN ,_, is_VBZ not_RB required_VBN for_IN patients_NNS with_IN type_NN
          2_CD diabetes_NN whose_WP$ diabetes_NN is_VBZ well_RB controlled_VBN with_IN diet_NN (_( i_NNP ._. e_SYM ._. ,_, fasting_VBG blood_NN glucose_NN less_JJR
          than_IN 125_CD mg_NN /_NN dl_NN )_) ._. However_RB ,_, insulin_NN should_MD still_RB be_VB administered_VBN as_IN described_VBN in_IN Box_NNP 2_CD ,_, as_IN
          hyperglycemic_JJ responses_NNS may_MD still_RB occur_VB intraoperatively_RB in_IN these_DT patients_NNS ._. Targeted_NNP
          glycemic_JJ levels_NNS are_VBP identical_JJ to_TO those_DT for_IN patients_NNS with_IN type_NN 1_CD diabetes_NN ._. For_IN elective_JJ
          procedures_NNS requiring_VBG general_JJ anesthesia_NN ,_, insulin_NN infusion_NN is_VBZ usually_RB required_VBN to_TO control_VB
          hyperglycemic_JJ levels_NNS that_WDT occur_VBP during_IN surgery_NN ._. Frequent_JJ intraoperative_JJ glucose_NN
          monitoring_VBG is_VBZ imperative_JJ in_IN this_DT setting_VBG to_TO avoid_VB complications_NNS resulting_VBG from_IN a_DT poor_JJ
          glycemic_JJ control_NN ._. Patients_NNS with_IN type_NN 2_CD diabetes_NN who_WP require_VBP insulin_NN and_CC who_WP are_VBP scheduled_VBN
          for_IN surgery_NN should_MD be_VB managed_VBN similarly_RB to_TO patients_NNS with_IN type_NN 1_CD diabetes_NN ._.
          As_IN a_DT general_JJ rule_NN ,_, SC_NNP insulin_NN should_MD not_RB be_VB used_VBN in_IN patients_NNS with_IN type_NN 2_CD diabetes_NN
          requiring_VBG surgery_NN and_CC general_JJ anesthesia_NN ,_, since_IN insulin_NN absorption_NN from_IN the_DT SC_NNP tissue_NN
          could_MD be_VB quite_RB variable_JJ ,_, particularly_RB in_IN obese_NN individuals_NNS ._.
          With_IN regard_NN to_TO patients_NNS with_IN type_NN 2_CD diabetes_NN who_WP require_VBP general_JJ anesthesia_NN and_CC whose_WP$
          diabetes_NN is_VBZ well_RB controlled_VBN with_IN sulfonylureas_NNS ,_, there_EX is_VBZ some_DT degree_NN of_IN disagreement_NN ._.
          Many_JJ diabetologists_NNS recommend_VBP withholding_VBG the_DT sulfonylurea_NN the_DT morning_NN of_IN surgery_NN for_IN
          procedures_NNS requiring_VBG general_JJ or_CC local_JJ anesthesia_NN and_CC using_VBG continuous_JJ insulin_NN
          infusion_NN ._.
          Any_DT patient_NN treated_VBN with_IN metformin_NN should_MD discontinue_VB this_DT medication_NN at_IN least_JJS 48_CD
          hours_NNS before_IN surgery_NN ._. The_DT drug_NN should_MD be_VB completely_RB cleared_VBN after_IN discontinuing_VBG metformin_NN
          48_CD hours_NNS preceding_VBG surgery_NN ._. This_DT is_VBZ a_DT prophylactic_JJ measure_NN in_IN an_DT effort_NN to_TO lower_VB the_DT risk_NN
          of_IN lactic_JJ acidosis_NNS that_WDT could_MD be_VB secondary_JJ to_TO complications_NNS of_IN surgical_JJ procedures_NNS such_JJ
          as_IN hypotension_NN ,_, myocardial_NN infarction_NN ,_, or_CC septic_JJ shock_NN ._.
          Treatment_NNP decisions_NNS for_IN patients_NNS with_IN type_NN 2_CD diabetes_NN receiving_VBG local_JJ anesthesia_NN and_CC
          undergoing_VBG minor_JJ surgical_JJ procedures_NNS are_VBP similar_JJ to_TO those_DT described_VBD above_IN for_IN patients_NNS
          with_IN type_NN 1_CD diabetes_NN ._.
        
      
      
        DISCUSSION_NNP
        Patients_NNS with_IN type_NN 1_CD diabetes_NN undergoing_VBG elective_JJ or_CC emergency_NN surgical_JJ procedures_NNS have_VBP
        a_DT higher_JJR degree_NN of_IN morbidity_NN and_CC mortality_NN than_IN those_DT without_IN diabetes_NN ,_, as_IN a_DT result_NN of_IN
        impaired_VBN glyco-metabolic_JJ homeostasis_NNS and_CC electrolyte_NN balance_NN ._. The_DT magnitude_NN of_IN the_DT
        catabolic_JJ responses_NNS is_VBZ not_RB only_RB related_VBN to_TO the_DT severity_NN of_IN surgical_JJ and_CC postsurgical_JJ
        complications_NNS but_CC also_RB to_TO the_DT effects_NNS of_IN inadequate_JJ perioperative_JJ management_NN on_IN metabolic_JJ
        control_NN ._. Health-care_JJ providers_NNS should_MD be_VB very_RB familiar_JJ with_IN the_DT perioperative_JJ management_NN of_IN
        type_NN 1_CD diabetes_NN ;_: with_IN individualized_JJ insulin_NN and_CC glucose_NN variable_JJ infusions_NNS ,_, young_JJ patients_NNS
        affected_VBN by_IN type_NN 1_CD diabetes_NN can_MD undergo_VB surgery_NN with_IN a_DT minimal_JJ risk_NN ._.
        The_DT goal_NN of_IN glycemic_JJ management_NN in_IN these_DT situations_NNS is_VBZ to_TO maintain_VB normal_JJ glucose_NN
        homeostasis_NNS and_CC normal_JJ metabolism_NN ._. As_IN insulin_NN resistance_NN and_CC gluconeogenesis_NNS increase_VBP
        during_IN surgery-related_JJ stress_NN and_CC anesthesia_NN ,_, additional_JJ insulin_NN will_MD be_VB needed_VBN to_TO prevent_VB
        excessive_JJ hepatic_JJ glucose_NN release_NN ._. An_DT important_JJ issue_NN is_VBZ maintaining_VBG a_DT physiological_JJ fluid_NN
        and_CC electrolyte_NN balance_NN ._.
        Perioperative_NNP hyperglycemia_NN increases_VBZ the_DT risk_NN of_IN infections_NNS ,_, delayed_VBN wound_VBD healing_VBG ,_, and_CC
        ischemia_NN ._. Achieving_NNP preprandial_NN glycemic_JJ levels_NNS between_IN 70_CD and_CC 150_CD mg_NN /_NN dl_NN before_IN surgery_NN in_IN
        the_DT preoperative_JJ period_NN and_CC maintaining_VBG plasma_NN glucose_NN levels_NNS between_IN 100_CD and_CC 125_CD mg_NN /_NN dl_NN
        during_IN surgery_NN and_CC between_IN 100_CD and_CC 150_CD mg_NN /_NN dl_NN after_IN surgery_NN using_VBG simple_JJ and_CC safe_JJ algorithms_NNS
        (_( Boxes_NNPS 1_CD ,_, 2_CD ,_, and_CC 4_LS )_) can_MD significantly_RB decrease_VB the_DT risk_NN of_IN these_DT complications_NNS ._.
      
    
  
